References
[1] Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC,
Burgel PR, Tullis E, Castanos C, Castellani C, Byrnes CA, Cathcart F,
Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P,
Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N,
Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O’Neill
C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL,
Zampoli M, Ratjen F: The future of cystic fibrosis care: a global
perspective. Lancet Respir Med 2020, 8:65-124.
[2] Elborn JS: Cystic fibrosis. Lancet 2016, 388:2519-31.
[3] Gibson RL, Burns JL, Ramsey BW: Pathophysiology and management
of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med
2003, 168:918-51.
[4] Stoltz DA, Meyerholz DK, Welsh MJ: Origins of cystic fibrosis
lung disease. N Engl J Med 2015, 372:1574-5.
[5] Tracy MC, Moss RB: The myriad challenges of respiratory fungal
infection in cystic fibrosis. Pediatr Pulmonol 2018, 53:S75-S85.
[6] Janahi IA, Rehman A, Al-Naimi AR: Allergic bronchopulmonary
aspergillosis in patients with cystic fibrosis. Ann Thorac Med 2017,
12:74-82.
[7] Amin R, Dupuis A, Aaron SD, Ratjen F: The effect of chronic
infection with Aspergillus fumigatus on lung function and
hospitalization in patients with cystic fibrosis. Chest 2010, 137:171-6.
[8] Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD,
Denning DW: Novel immunologic classification of aspergillosis in adult
cystic fibrosis. J Allergy Clin Immunol 2013, 132:560-6 e10.
[9] King J, Brunel SF, Warris A: Aspergillus infections in cystic
fibrosis. J Infect 2016, 72 Suppl:S50-5.
[10] Antunes J, Fernandes A, Borrego LM, Leiria-Pinto P, Cavaco J:
Cystic fibrosis, atopy, asthma and ABPA. Allergol Immunopathol (Madr)
2010, 38:278-84.
[11] Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP:
Prevalence and risk factors for recovery of filamentous fungi in
individuals with cystic fibrosis. J Cyst Fibros 2010, 9:110-6.
[12] de Vrankrijker AM, van der Ent CK, van Berkhout FT, Stellato
RK, Willems RJ, Bonten MJ, Wolfs TF: Aspergillus fumigatus colonization
in cystic fibrosis: implications for lung function? Clin Microbiol
Infect 2011, 17:1381-6.
[13] Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan
JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL: Effect of chronic
intermittent administration of inhaled tobramycin on respiratory
microbial flora in patients with cystic fibrosis. J Infect Dis 1999,
179:1190-6.
[14] Keown K, Reid A, Moore JE, Taggart CC, Downey DG: Coinfection
with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic
fibrosis. Eur Respir Rev 2020, 29.
[15] Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs
N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I,
Southern KW, Marshall BC, Sosnay PR: Diagnosis of Cystic Fibrosis:
Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr
2017, 181S:S4-S15 e1.
[16] Saiman L, Siegel J, Cystic Fibrosis F: Infection control
recommendations for patients with cystic fibrosis: microbiology,
important pathogens, and infection control practices to prevent
patient-to-patient transmission. Infect Control Hosp Epidemiol 2003,
24:S6-52.
[17] Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A,
Ramsey BW, Rowe SM, Network GIotCFFTD: Pseudomonas aeruginosa in cystic
fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect
Dis 2015, 60:703-12.
[18] Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM:
Evaluation of a new definition for chronic Pseudomonas aeruginosa
infection in cystic fibrosis patients. J Cyst Fibros 2003, 2:29-34.
[19] Kent BD, Lane SJ, van Beek EJ, Dodd JD, Costello RW, Tiddens
HA: Asthma and cystic fibrosis: a tangled web. Pediatr Pulmonol 2014,
49:205-13.
[20] Nielsen AO, Qayum S, Bouchelouche PN, Laursen LC, Dahl R, Dahl
M: Risk of asthma in heterozygous carriers for cystic fibrosis: A
meta-analysis. J Cyst Fibros 2016, 15:563-7.
[21] Nguyen LD, Viscogliosi E, Delhaes L: The lung mycobiome: an
emerging field of the human respiratory microbiome. Front Microbiol
2015, 6:89.
[22] Kaur S, Singh S: Biofilm formation by Aspergillus fumigatus.
Med Mycol 2014, 52:2-9.
[23] Mowat E, Rajendran R, Williams C, McCulloch E, Jones B, Lang S,
Ramage G: Pseudomonas aeruginosa and their small diffusible
extracellular molecules inhibit Aspergillus fumigatus biofilm formation.
FEMS Microbiol Lett 2010, 313:96-102.
[24] Akil N, Muhlebach MS: Biology and management of methicillin
resistant Staphylococcus aureus in cystic fibrosis. Pediatr Pulmonol
2018, 53:S64-S74.
[25] Cabaret O, Bonnal C, Canoui-Poitrine F, Emirian A, Bizouard G,
Levesque E, Maitre B, Fihman V, Decousser JW, Botterel F: Concomitant
presence of Aspergillus fumigatus and Stenotrophomonas maltophilia in
the respiratory tract: a new risk for patients with liver disease? J Med
Microbiol 2016, 65:414-9.
[26] Foundation CF: 2019 Patient Registry Annual Data Report. 2020.
[27] Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D,
Bouchara JP: Clinical significance of Scedosporium apiospermum in
patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000,
19:53-6.
[28] Chotirmall SH, McElvaney NG: Fungi in the cystic fibrosis lung:
bystanders or pathogens? Int J Biochem Cell Biol 2014, 52:161-73.
[29] Coron N, Pihet M, Frealle E, Lemeille Y, Pinel C, Pelloux H,
Gargala G, Favennec L, Accoceberry I, Durand-Joly I, Dalle F, Huet F,
Fanton A, Boldron A, Loeuille GA, Domblides P, Coltey B, Pin I, Llerena
C, Troussier F, Person C, Marguet C, Wizla N, Thumerelle C, Turck D, Bui
S, Fayon M, Duhamel A, Prevotat A, Wallaert B, Leroy S, Bouchara JP,
Delhaes L: Toward the Standardization of Mycological Examination of
Sputum Samples in Cystic Fibrosis: Results from a French Multicenter
Prospective Study. Mycopathologia 2018, 183:101-17.